



Practitioner's Docket No. MPI00-459P1RM (previously 10147-56U1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Meyers, Rachel E., et al
Application No.: 10/001,851 Group No.: 1635
Filed: November 20, 2001 Examiner: James Schultz
For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES
THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction Requirement dated October 6, 2003 (Paper No. 10), the claims of Group IX (claims 27-31 and 34-35), drawn to a method for assessing whether a test compound is useful for modulating a phenomenon comprising adding the test compound to a first composition comprising SEQ ID NO:2, are elected for prosecution without traverse. In order to be fully responsive, Applicants hereby elect to prosecute the claims drawn to "tumorigenesis" without prejudice to Applicant's right to pursue the non-elected subject matter in other applications in the event a generic claim is not found allowable. Applicants hereby

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:


MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a) **37 C.F.R. SECTION 1.10***

☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.



Signature
Sean Hunziker
(type or print name of person certifying)

Date: November 14, 2003

**WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

reserve the right to traverse the above restriction with respect to non-elected Groups I-VIII and X-XVI in this or subsequent applications.

This paper is being filed timely as Applicants believe that a one month extension of time is required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

November 14, 2003

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820